Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Oncology Reports|July 5, 2016
EGFR and KRAS mutational analysis in a large series of Italian non-small cell lung cancer patients: 2,387 cases from a single centerRiccardo Giannini, Cristiana Lupi, Elisa Sensi, et al.
British Journal of Cancer|February 9, 2023
Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs' developmentRoberto Moretto, Marco Maria Germani, Mirella Giordano, et al.
JCO Precision Oncology|October 5, 2023
Predictive Impact of RNF43 Mutations in Patients With Proficient Mismatch Repair/Microsatellite Stable BRAFV600E-Mutated Metastatic Colorectal Cancer Treated With Target Therapy or ChemotherapyRoberto Moretto, Marco Maria Germani, Javier Ros, et al.
Journal for Immunotherapy of Cancer|April 21, 2023
Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE studyRoberto Moretto, Daniele Rossini, Aurélie Catteau, et al.
European Journal of Cancer (Oxford, England : 1990)|June 14, 2021
Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 studyRoberto Moretto, Mirella Giordano, Anello M Poma, et al.
JCO Precision Oncology|April 18, 2025
Exploring the Prognostic and Predictive Impact of Genomic Loss of Heterozygosity and Homologous Recombination Deficiency Alterations in Patients With Metastatic Colorectal CancerRoberto Moretto, Marco Maria Germani, Martina Carullo, et al.
Frontiers in Oncology|February 26, 2024
Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trialMarco Maria Germani, Guglielmo Vetere, Mirella Giordano, et al.
JCO Precision Oncology|May 11, 2022
Negative Ultraselection of Patients With RAS/BRAF Wild-Type, Microsatellite-Stable Metastatic Colorectal Cancer Receiving Anti-EGFR-Based TherapyGiovanni Randon, Giulia Maddalena, Marco Maria Germani, et al.
European Journal of Cancer (Oxford, England : 1990)|March 1, 2022
Early modulation of Angiopoietin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancerCarlotta Antoniotti, Federica Marmorino, Alessandra Boccaccino, et al.
European Journal of Cancer (Oxford, England : 1990)|April 2, 2022
FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studiesCarlotta Antoniotti, Marco M Germani, Daniele Rossini, et al.
Pageof 4